The Economic Times reported 2 days ago that NATCO pharma has applied for a compulsory license for Bayer’s patented drug Nexavar, which is used to treat liver and kidney cancer.
This is not a surprising development because earlier this year there was talk in the air about generic drug makers like Cipla and Natco planning to actively explore the compulsory licensing mechanism.
This is expected to be a long-drawn affair (what’s new? Almost every patent proceeding is a long-drawn affair in India). We’ll keep our readers posted on any further developments on this front.
I thank Disha Jeswani for bringing this development to my attention!
I thank Disha Jeswani for bringing this development to my attention!
No comments:
Post a Comment